Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $60.06 USD
Change Today +1.56 / 2.67%
Volume 5.2M
As of 8:04 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/15 - $72.31
52 Week Low
10/15/14 - $47.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $3.3M
Compensation as of Fiscal Year 2014.

teva pharmaceutical-sp adr (TEVA) Key Developments

Teva Pharmaceutical Industries Limited Proposes Amendments to Articles of Association and Memorandum of Association

Teva Pharmaceutical Industries Limited will propose amendments to the company's Articles of Association and Memorandum of Association at the Special Meeting of Shareholders to be held on November 5, 2015.

Teva Pharmaceutical Industries Limited Announces Results from Two Phase 2B Studies of TEV-48125

Teva Pharmaceutical Industries Ltd. announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b studies of TEV-48125, a monoclonal anti-calcitonin gene-related peptide (CGRP) antibody investigational treatment for the prevention of chronic migraine and high frequency episodic migraine (HFEM). The Lancet Neurology ranks first among 194 journals in the clinical neurology category (2013 Journal Citation Reports®, Thomson Reuters 2014). The Phase 2b clinical development program consistently met all primary and secondary efficacy and safety endpoints for TEV-48125 in 564 patients and across multiple doses. Clinical improvements were exhibited after a single administration of all tested doses of TEV-48125 in both episodic and chronic migraine studies. These results were achieved in the presence of patients being allowed to remain on existing migraine prevention therapy and the results demonstrated significant separation in favor of TEV-48125 even in patients considered to be failing current optimal therapy.

Teva Pharmaceutical Industries Ltd. Presents Results from Post Hoc Analysis of Two Pivotal Phase III Clinical Trials

Teva Pharmaceutical Industries Ltd. presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75% versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS). Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for which Teva is seeking approval in the treatment of asthma in patients with elevated blood eosinophils who are inadequately controlled on an ICS-based regimen. These results were presented as a late-breaking abstract at the 2015 ERS International Congress in Amsterdam. Asthma diagnosed after the age of 40 falls into a distinct subtype which is often very challenging to treat, commented abstract author, Professor Guy Brusselle, Ghent University Hospital, Belgium. These latest results for reslizumab are therefore particularly encouraging, as they indicate that the drug, in combination with standard of care therapy, may provide these patients with a much-needed new option to help alleviate their symptoms and significantly improve their asthma control.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $60.06 USD +1.56

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.38 USD +0.62
AbbVie Inc $55.82 USD +0.69
AstraZeneca PLC 4,168 GBp +7.00
Biogen Inc $290.35 USD +3.05
Eli Lilly & Co $87.52 USD +2.34
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVA Industry Range
Price/Earnings 20.3x
Price/Sales 2.5x
Price/Book 2.2x
Price/Cash Flow 22.6x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at